The tamoxifen market was valued at USD 675.7 Mn in 2015, and is expected to reach USD 683.6 Mn by 2022, expanding at a CAGR of 0.07% from 2016 to 2022.
Tamoxifen is the oldest and among the most prescribed selective estrogen receptor modulator for breast cancer treatment and management. Tamoxifen is approved for early stage, hormone receptor positive breast cancer in men and women, after surgery or chemotherapy to reduce recurrence risk, and for management of advanced stage or metastatic hormone-receptor positive breast cancer. Women at high risk of developing breast cancer also use Tamoxifen. Tamoxifen is at the maturity stage of product life cycle and is anticipated to experience decline in market growth in the light of introduction of advanced breast cancer management drugs.
This report analyzes the geographical distribution of tamoxifen market in North America, Europe, Asia-Pacific and Rest of the World markets. Currently, North America is the largest market for tamoxifen drugs and it is anticipated that the lead of this region will continue through 2022. Large pool of breast cancer patients, high awareness for breast cancer screening and prevention, well-structured reimbursement scenario and large pool of breast cancer patients. Asia-Pacific and Rest of the World markets will experience the fastest CAGR during 2016-2022. Improving awareness in Middle East and Africa, high incidence of late stage breast cancer in these regions and rapid development of healthcare infrastructure are the prime drivers of Rest of the World market.
- Allergen plc
- Apotex, Inc
- Astra Zeneca plc
- Mylan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Tamoxifen: Market Dynamics and Outlook
Chapter 4 Global Tamoxifen Market, Pipeline Analysis
Chapter 5 Global Tamoxifen Market, by Geography
Chapter 6 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/sjxh5r/global_tamoxifen